Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Revenue (2016 - 2026)

Cytosorbents filings provide 15 years of Revenue readings, the most recent being $9.2 million for Q4 2025.

  • On a quarterly basis, Revenue rose 0.91% to $9.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $37.1 million, a 4.12% increase, with the full-year FY2025 number at $37.1 million, up 4.12% from a year prior.
  • Revenue hit $9.2 million in Q4 2025 for Cytosorbents, down from $9.5 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $12.0 million in Q2 2021 to a low of $8.1 million in Q3 2022.
  • Median Revenue over the past 5 years was $9.2 million (2024), compared with a mean of $9.3 million.
  • Biggest five-year swings in Revenue: rose 22.76% in 2021 and later decreased 29.35% in 2022.
  • Cytosorbents' Revenue stood at $10.8 million in 2021, then fell by 12.91% to $9.4 million in 2022, then dropped by 7.69% to $8.7 million in 2023, then grew by 5.57% to $9.2 million in 2024, then increased by 0.91% to $9.2 million in 2025.
  • The last three reported values for Revenue were $9.2 million (Q4 2025), $9.5 million (Q3 2025), and $9.6 million (Q2 2025) per Business Quant data.